Dr Sean O'Cathail
- Honorary Clinical Senior Lecturer (School of Cancer Sciences)
email:
Sean.OCathail@glasgow.ac.uk
Cork University Hospital, Wilton, Cork, T12 DC4A
Publications
2024
Hillson, L. V. S., McCulloch, A. K., Edwards, J. , Dunne, P. D., O'Cathail, S. M. and Roxburgh, C. S. (2024) Radiation-induced changes in gene expression in rectal cancer specimens. Clinical and Translational Oncology, (doi: 10.1007/s12094-023-03361-9) (PMID:38243085) (Early Online Publication)
2023
Beach, C. et al. (2023) Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. Journal of Clinical Investigation, 133(23), e168277. (doi: 10.1172/JCI168277) (PMID:37824211) (PMCID:PMC10688992)
McMahon, R. K., O'Cathail, S. M. , Nair, H., Steele, C. W. , Platt, J. J., Digby, M., McDonald, A. C., Horgan, P. G. and Roxburgh, C. S.D. (2023) The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer. Colorectal Disease, 25(9), pp. 1783-1794. (doi: 10.1111/codi.16667) (PMID:37485654)
Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)
2022
O'Cathail, S.M. and Chalmers, A.J. (2022) Integrating novel cancer therapies with radiation - illuminating the tunnel. Clinical Oncology, 35(1), pp. 38-41. (doi: 10.1016/j.clon.2022.10.010) (PMID:36333159)
Devlin, L., Grocutt, L., Hunter, B., Chemu, H., Duffton, A., McDonald, A., Macleod, N., McLoone, P. and O'Cathail, S. M. (2022) The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer. Clinical and Translational Radiation Oncology, 36, pp. 24-30. (doi: 10.1016/j.ctro.2022.06.003) (PMID:35756193) (PMCID:PMC9218294)
Robinson, M., O'Cathail, S. , Duffton, A., Aitken, K. and Muirhead, R. (2022) Potential for isotoxic re-irradiation stereotactic ablative body radiotherapy in locally recurrent rectal cancer. Clinical Oncology, 34(9), pp. 571-577. (doi: 10.1016/j.clon.2022.04.007) (PMID:35504797)
2021
O'Cathail, S. M. , Wu, C.-H., Thomas, R., Hawkins, M. A., Maughan, T. S. and Lewis, A. (2021) NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch. Antioxidants, 10(9), 1380. (doi: 10.3390/antiox10091380)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)
Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)
2020
Smith, T., O'Cathail, S. M. , Silverman, S., Robinson, M., Tsang, Y., Harrison, M. and Hawkins, M. A. (2020) Stereotactic Body Radiotherapy re-irradiation for locally recurrent rectal cancer: outcomes and toxicity. Advances in Radiation Oncology, 5(6), pp. 1311-1319. (doi: 10.1016/j.adro.2020.07.017) (PMID:33305093) (PMCID:PMC7718547)
O'Cathail, S. M. , Smith, T., Owens, R., Zeniou, A., Tsang, Y., Holyoake, D. L.P., Murray, L., Harrison, M. and Hawkins, M. A. (2020) Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 151, pp. 280-286. (doi: 10.1016/j.radonc.2020.08.012) (PMID:32866563) (PMCID:PMC7689579)
O'Cathail, S. M. , Wu, C.-H., Lewis, A., Holmes, C., Hawkins, M. A. and Maughan, T. (2020) NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 248, pp. 1-10. (doi: 10.1016/j.cancergen.2020.08.006) (PMID:32871287)
O'Cathail, S.M. , Gilbert, D.C., Sebag-Montefiore, D. and Muirhead, R. (2020) Challenges and consequences of COVID-19 in the management of anorectal cancer: coming together through social distancing. Clinical Oncology, 32(7), pp. 413-416. (doi: 10.1016/j.clon.2020.04.009) (PMID:32359847) (PMCID:PMC7184022)
O'Cathail, S. M. et al. (2020) A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 15, 151. (doi: 10.1186/s13014-020-01593-5) (PMID:32532291) (PMCID:PMC7291514)
Cooke, R., Camilleri, P., Chu, K.-Y., O'Cathail, S. M. , Robinson, M., Van Den Heuvel, F. and Hawkins, M. A. (2020) Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: initial outcomes. Technical Innovations and Patient Support in Radiation Oncology, 13, pp. 24-30. (doi: 10.1016/j.tipsro.2020.01.002) (PMID:32128460) (PMCID:PMC7042153)
2019
Rayner, E., Durin, M.-A., Thomas, R., Moralli, D., O'Cathail, S. M. , Tomlinson, I., Green, C. M. and Lewis, A. (2019) CRISPR-Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods. CRISPR Journal, 2(6), pp. 406-416. (doi: 10.1089/crispr.2019.0006) (PMID:31742432) (PMCID:PMC6919265)
O'Cathail, S.M. and Buffa, F.M. (2019) Science in focus: bioinformatics part 1 – lost in translation. Clinical Oncology, 31(6), pp. 337-340. (doi: 10.1016/j.clon.2019.03.043) (PMID:30975523)
2018
O'Cathail, S. M. , Karir, N. and Shah, K. (2018) Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – a retrospective dosimetry review and feasibility planning study. Oral Oncology, 76, pp. 16-21. (doi: 10.1016/j.oraloncology.2017.11.020) (PMID:29290281)
2017
O'Cathail, S. M. , Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W. and Hawkins, M. A. (2017) Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization. Frontiers in Oncology, 7, 153. (doi: 10.3389/fonc.2017.00153) (PMID:28791251) (PMCID:PMC5523729)
Muirhead, R., Drinkwater, K., O'Cathail, S.M. , Adams, R., Glynne-Jones, R., Harrison, M., Hawkins, M.A., Sebag-Montefiore, D. and Gilbert, D.C. (2017) Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology, 29(3), pp. 188-197. (doi: 10.1016/j.clon.2016.10.005) (PMID:27810119) (PMCID:PMC5304408)
Cox, S. J., O'Cathail, S. M. , Coles, B., Crosby, T. and Mukherjee, S. (2017) Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas. Current Oncology Reports, 19(1), 7. (doi: 10.1007/s11912-017-0559-8) (PMID:28213876) (PMCID:PMC5315732)
2015
Higgins, G. S., O'Cathail, S. M. , Muschel, R. J. and McKenna, W. G. (2015) Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treatment Reviews, 41(2), pp. 105-113. (doi: 10.1016/j.ctrv.2014.12.012) (PMID:25579753)
2014
Ramaswami, R., O'Cathail, S. M. , Brindley, J. H., Silcocks, P., Mahmoud, S. and Palmieri, C. (2014) Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncology, 10(3), pp. 363-376. (doi: 10.2217/fon.13.210) (PMID:24367990)
Stavraka, C., Pinato, D. J., Turnbull, S. J., Flynn, M. J., Forster, M. D., O'Cathail, S. M. , Babar, S., Seckl, M. J., Kristeleit, R. S. and Blagden, S. P. (2014) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer, 120(2), pp. 262-270. (doi: 10.1002/cncr.28381) (PMID:24399418)
Scarpa, A. et al. (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS ONE, 9(1), e83279. (doi: 10.1371/journal.pone.0083279) (PMID:24409281) (PMCID:PMC3883636)
2013
O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)
2012
O'Cathail, S. and Stebbing, J. (2012) Ayurveda: alternative or complementary? Lancet Oncology, 13(9), p. 865. (doi: 10.1016/S1470-2045(12)70405-9) (PMID:22935233)
2011
O'Cathail, S.M. , O'Connell, O.J., Long, N., Morgan, M., Eustace, J.A., Plant, B.J. and Hourihane, J.O.'.B. (2011) Association of cigarette smoking with drug use and risk taking behaviour in Irish teenagers. Addictive Behaviors, 36(5), pp. 547-550. (doi: 10.1016/j.addbeh.2011.01.012) (PMID:21315520)
Articles
Hillson, L. V. S., McCulloch, A. K., Edwards, J. , Dunne, P. D., O'Cathail, S. M. and Roxburgh, C. S. (2024) Radiation-induced changes in gene expression in rectal cancer specimens. Clinical and Translational Oncology, (doi: 10.1007/s12094-023-03361-9) (PMID:38243085) (Early Online Publication)
Beach, C. et al. (2023) Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. Journal of Clinical Investigation, 133(23), e168277. (doi: 10.1172/JCI168277) (PMID:37824211) (PMCID:PMC10688992)
McMahon, R. K., O'Cathail, S. M. , Nair, H., Steele, C. W. , Platt, J. J., Digby, M., McDonald, A. C., Horgan, P. G. and Roxburgh, C. S.D. (2023) The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer. Colorectal Disease, 25(9), pp. 1783-1794. (doi: 10.1111/codi.16667) (PMID:37485654)
Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)
O'Cathail, S.M. and Chalmers, A.J. (2022) Integrating novel cancer therapies with radiation - illuminating the tunnel. Clinical Oncology, 35(1), pp. 38-41. (doi: 10.1016/j.clon.2022.10.010) (PMID:36333159)
Devlin, L., Grocutt, L., Hunter, B., Chemu, H., Duffton, A., McDonald, A., Macleod, N., McLoone, P. and O'Cathail, S. M. (2022) The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer. Clinical and Translational Radiation Oncology, 36, pp. 24-30. (doi: 10.1016/j.ctro.2022.06.003) (PMID:35756193) (PMCID:PMC9218294)
Robinson, M., O'Cathail, S. , Duffton, A., Aitken, K. and Muirhead, R. (2022) Potential for isotoxic re-irradiation stereotactic ablative body radiotherapy in locally recurrent rectal cancer. Clinical Oncology, 34(9), pp. 571-577. (doi: 10.1016/j.clon.2022.04.007) (PMID:35504797)
O'Cathail, S. M. , Wu, C.-H., Thomas, R., Hawkins, M. A., Maughan, T. S. and Lewis, A. (2021) NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch. Antioxidants, 10(9), 1380. (doi: 10.3390/antiox10091380)
Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)
Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)
Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)
Smith, T., O'Cathail, S. M. , Silverman, S., Robinson, M., Tsang, Y., Harrison, M. and Hawkins, M. A. (2020) Stereotactic Body Radiotherapy re-irradiation for locally recurrent rectal cancer: outcomes and toxicity. Advances in Radiation Oncology, 5(6), pp. 1311-1319. (doi: 10.1016/j.adro.2020.07.017) (PMID:33305093) (PMCID:PMC7718547)
O'Cathail, S. M. , Smith, T., Owens, R., Zeniou, A., Tsang, Y., Holyoake, D. L.P., Murray, L., Harrison, M. and Hawkins, M. A. (2020) Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. Radiotherapy and Oncology, 151, pp. 280-286. (doi: 10.1016/j.radonc.2020.08.012) (PMID:32866563) (PMCID:PMC7689579)
O'Cathail, S. M. , Wu, C.-H., Lewis, A., Holmes, C., Hawkins, M. A. and Maughan, T. (2020) NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 248, pp. 1-10. (doi: 10.1016/j.cancergen.2020.08.006) (PMID:32871287)
O'Cathail, S.M. , Gilbert, D.C., Sebag-Montefiore, D. and Muirhead, R. (2020) Challenges and consequences of COVID-19 in the management of anorectal cancer: coming together through social distancing. Clinical Oncology, 32(7), pp. 413-416. (doi: 10.1016/j.clon.2020.04.009) (PMID:32359847) (PMCID:PMC7184022)
O'Cathail, S. M. et al. (2020) A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 15, 151. (doi: 10.1186/s13014-020-01593-5) (PMID:32532291) (PMCID:PMC7291514)
Cooke, R., Camilleri, P., Chu, K.-Y., O'Cathail, S. M. , Robinson, M., Van Den Heuvel, F. and Hawkins, M. A. (2020) Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: initial outcomes. Technical Innovations and Patient Support in Radiation Oncology, 13, pp. 24-30. (doi: 10.1016/j.tipsro.2020.01.002) (PMID:32128460) (PMCID:PMC7042153)
Rayner, E., Durin, M.-A., Thomas, R., Moralli, D., O'Cathail, S. M. , Tomlinson, I., Green, C. M. and Lewis, A. (2019) CRISPR-Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods. CRISPR Journal, 2(6), pp. 406-416. (doi: 10.1089/crispr.2019.0006) (PMID:31742432) (PMCID:PMC6919265)
O'Cathail, S.M. and Buffa, F.M. (2019) Science in focus: bioinformatics part 1 – lost in translation. Clinical Oncology, 31(6), pp. 337-340. (doi: 10.1016/j.clon.2019.03.043) (PMID:30975523)
O'Cathail, S. M. , Karir, N. and Shah, K. (2018) Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – a retrospective dosimetry review and feasibility planning study. Oral Oncology, 76, pp. 16-21. (doi: 10.1016/j.oraloncology.2017.11.020) (PMID:29290281)
O'Cathail, S. M. , Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W. and Hawkins, M. A. (2017) Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization. Frontiers in Oncology, 7, 153. (doi: 10.3389/fonc.2017.00153) (PMID:28791251) (PMCID:PMC5523729)
Muirhead, R., Drinkwater, K., O'Cathail, S.M. , Adams, R., Glynne-Jones, R., Harrison, M., Hawkins, M.A., Sebag-Montefiore, D. and Gilbert, D.C. (2017) Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology, 29(3), pp. 188-197. (doi: 10.1016/j.clon.2016.10.005) (PMID:27810119) (PMCID:PMC5304408)
Cox, S. J., O'Cathail, S. M. , Coles, B., Crosby, T. and Mukherjee, S. (2017) Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas. Current Oncology Reports, 19(1), 7. (doi: 10.1007/s11912-017-0559-8) (PMID:28213876) (PMCID:PMC5315732)
Higgins, G. S., O'Cathail, S. M. , Muschel, R. J. and McKenna, W. G. (2015) Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treatment Reviews, 41(2), pp. 105-113. (doi: 10.1016/j.ctrv.2014.12.012) (PMID:25579753)
Ramaswami, R., O'Cathail, S. M. , Brindley, J. H., Silcocks, P., Mahmoud, S. and Palmieri, C. (2014) Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncology, 10(3), pp. 363-376. (doi: 10.2217/fon.13.210) (PMID:24367990)
Stavraka, C., Pinato, D. J., Turnbull, S. J., Flynn, M. J., Forster, M. D., O'Cathail, S. M. , Babar, S., Seckl, M. J., Kristeleit, R. S. and Blagden, S. P. (2014) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer, 120(2), pp. 262-270. (doi: 10.1002/cncr.28381) (PMID:24399418)
Scarpa, A. et al. (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS ONE, 9(1), e83279. (doi: 10.1371/journal.pone.0083279) (PMID:24409281) (PMCID:PMC3883636)
O'Cathail, S. M. , Shaboodien, R., Mahmoud, S., Carty, K., O'Sullivan, P., Blagden, S., Gabra, H., Whear, S., Kwon, J. S. and Agarwal, R. (2013) Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies. International Journal of Gynecologic Cancer, 23(7), pp. 1318-1325. (doi: 10.1097/IGC.0b013e31829f1799) (PMID:23907557)
O'Cathail, S. and Stebbing, J. (2012) Ayurveda: alternative or complementary? Lancet Oncology, 13(9), p. 865. (doi: 10.1016/S1470-2045(12)70405-9) (PMID:22935233)
O'Cathail, S.M. , O'Connell, O.J., Long, N., Morgan, M., Eustace, J.A., Plant, B.J. and Hourihane, J.O.'.B. (2011) Association of cigarette smoking with drug use and risk taking behaviour in Irish teenagers. Addictive Behaviors, 36(5), pp. 547-550. (doi: 10.1016/j.addbeh.2011.01.012) (PMID:21315520)